|
Consensus recommendations |
Grade |
|
Routine on-treatment HCV PCR testing is not required as it is unlikely to change management. Quantitative HCV PCR testing should be considered if there are concerns about DAA adherence or viral resistance. |
B1 |
|
Qualitative HCV PCR testing at the end of treatment is reasonable to confirm an end-of-treatment response; however, given the high efficacy of DAA therapy, such monitoring is not mandated in all individuals. |
C2 |